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Abstract
Background: Tetramethylpyrazine (TMP), an active ingredient in the traditional Chinese herbal medicine Rhizoma
Chuanxiong, has been used clinically for the prevention and treatment of cardiovascular disease. The benefits of
TMP are largely attributed to its anti-oxidative and vasodilative properties. However, the efficacy of TMP in the
treatment of pulmonary hypertension (PH) is unknown. We hypothesized that TMP may have a therapeutic effect in
patients with PH.
Methods/design: A randomized, single-blinded, clinical study with a TMP treatment group and a control group
will be conducted to evaluate the efficacy and safety of TMP intervention in patients with PH. The recruitment
target is 120 subjects meeting the following criteria: (i) at rest and at sea level, mean pulmonary artery pressure
above 20 mmHg and pulmonary capillary wedge pressure below 15 mmHg; (ii) type 1 or 4 PH in the stable phase;
(iii) age 15–70 years; (iv) 6-min walk distance between 100 and 450m; (v) World Health Organization (WHO) functional
classification of pulmonary hypertension of II, III, or IV. Subjects will be assigned randomly into two groups at a ratio of
1:2 (control:TMP). Both groups will receive routine treatment, and the treatment group will also receive oral TMP (100
mg) three times a day for 16 weeks. All patients will be followed up for 4, 8, 12, and 16 weeks; symptoms and patient
compliance will be recorded.
Discussion: We aimed to determine the efficacy and safety of TMP for the treatment of PH.
Trial registration: Chinese Clinical Trial Register, ChiCTR1800018664. Registered on 2 October 2018.
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Background
Pulmonary hypertension (PH) is a serious condition charac-
terized by sustained elevated mean pulmonary arterial pres-
sure over 20mmHg and progressive right ventricle
hypertrophy, leading to cardiac failure and even death [1–5].
With improvements in diagnostic techniques, PH is no
longer a rare disease. According to the latest epidemiological
data, the prevalence of PH is about 1% of the global popula-
tion [6]. Understanding of the pathophysiology and patho-
genesis of PH has increased and life quality of patients has
improved significantly through the use of targeted drugs;
however, combination therapy is more effective than mono-
therapy, so it is important to find new drugs to improve effi-
cacy [7–10]. In addition, the use of effective drugs is limited
by their high cost, which largely restricts PH patients in de-
veloping countries accessing treatment because of the eco-
nomic burden of these treatments. Therefore, it is imperative
to develop new and affordable medications with strong effi-
cacy and safety profiles.
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Given its anti-oxidative, anti-myocardial injury, and
vasodilative effects [11–14], tetramethylpyrazine (TMP),
a traditional Chinese herbal medicine, is widely used in
the treatment of cardiovascular and cerebrovascular dis-
eases [15–18]. The pathogenesis of PH involves oxidative
stress, vascular inflammation, and imbalance of intracel-
lular calcium homeostasis [19–21]. In our previous
study, we showed in a rat model of PH that TMP inter-
vention improves calcium imbalance in pulmonary ar-
tery smooth muscle cells (PASMCs) by modulating the
expression of TRPC1, TRPC6, Kv1.5, and Kv2.1, poten-
tially through reducing the intracellular free calcium
concentration to inhibit the contraction and prolifera-
tion of PASMCs and the remodeling of distal small pul-
monary arteries. However, it has not yet been reported
whether TMP has a therapeutic effect on PH. We there-
fore designed a 16-week, randomized, single-blinded,
clinically controlled study to examine the efficacy and
safety of TMP phosphate for the treatment of PH.
Methods/design
Study design
We designed a protocol for a randomized controlled
study. Screening (visit 0) is undertaken within 3 days prior
to enrollment to assess eligibility and collect baseline data.
Subjects who enter the primary screening are assessed for
lung function, and those meeting all criteria will be
randomly assigned (2:1) into a TMP treatment group or
control group. Both groups will receive conventional treat-
ment, but patients in the TMP treatment group will add-
itionally receive 100mg oral TMP (t.i.d). Patients will be
followed up at week-4 after randomization (visit 1), and
then followed up every 4 weeks until the end of treatment
at 16 weeks. Data collected at visit 0 include patient char-
acteristics (name, sex, age), medical history, concomitant
medications, laboratory and auxiliary examinations, and
adverse events. Additionally, at each visit, medical history,
medications, cardiac and pulmonary function, and adverse
events will be collected. Additional items will be evaluated
at visits 2 and 4. A schedule of assessments is shown in
Table 1. A study flow chart is shown in Fig. 1.
Sampling
Based on the 6-min walk distance (6MWD) as one of
the main efficacy indexes, it is assumed that, after treat-
ment, the experimental group will be able to walk an
average distance of 60 m further than the control group
in 6 min, with standard deviation of 60 m, α of 0.05, and










Table 1 Study schedule of assessments
Visit cycle evaluation projects Screening stage Visit 1 Visit 2 Visit 3 Visit 4
Time-Window Day −3–0 Week 4 Week 8 Week 12 Week 16
Inclusion and exclusion criteria √
Informed consent √
Basic condition √
Basic medical history √
Complication √ √ √ √ √
Symptoms and signs √ √ √ √ √
Drug combination √ √ √ √ √
Blood routine test, urine routine, liver and kidney function, coagulation function √ √
Evaluation of cardiopulmonary function (6MWD, WHO-FC, Borg Score, MLHFQ) √ √ √ √
Electrocardiogram √ √
Imaging √
Arterial blood gases √ √
NT-proBNP, cTNI levels √ √
Echocardiography √ √ √
Pulmonary function test √ √ √
Adverse events √ √ √ √
√, required
Basic medical history contains current medical history (symptoms and signs) and previous history
Evaluation of cardiac and pulmonary function includes a 6-min walk distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Borg Score,
and World Health Organization functional class (WHO-FC)
Safety parameters include routine blood tests and urinalysis, liver and kidney function, and coagulation function
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where q1 is the proportion of the experimental group
and q2 is the proportion of the control group, q1 = 2/3,
q2 = 1/3, N ≈ 107.
Assuming a dropout rate of 11%, the required sample
size is approximately 120 participants, comprising 40 pa-
tients in the control group and 80 patients in the TMP
group.
Study procedure
Eligibility criteria for enrollment
The selection of participants will be based on the follow-
ing inclusion and exclusion criteria.
Inclusion criteria
1. In accordance with the diagnostic criteria for PH,
mean pulmonary arterial pressure measured by
right cardiac catheterization above 20 mmHg and
pulmonary capillary wedge pressure below 15
mmHg at sea level and pulmonary vascular
resistance > 3 WU in a resting state.
2. Subjects with type 1 or type 4 PH classified
according to the World Symposium on
Pulmonary Hypertension [21] who are in a stable
stage (under regular medications without
fluctuation in one month), including idiopathic
PH, hereditary PH, PH induced by drugs or
toxins, PH associated with connective tissue
diseases or congenital heart diseases (with no
surgery/intervention within the previous 6
months) and chronic thromboembolic PH. For
type 4 patients, surgical treatment is preferred
for patients with surgical indications; patients
with PH after surgery, patients without surgical
indications, and nonoperable cases will undergo
stabilization with anticoagulant drugs (such as
warfarin) for at least 1 month prior to study
participation.
3. Aged between 15 and 70 years, male or female.
4. WHO PAH functional classification II, IV, or V.
5. 6MWD of > 100 m and < 450 m at baseline.
Fig. 1 Flow chart for enrollment and follow-up of participants
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6. Patients stable for at least 1 month after standard
treatment, and patients who have not received
treatment with interventional or surgical closure
in the 6 months prior to participation.
7. Patient or his/her guardian agrees to participation
of the patient in the study and provides written
informed consent for participation.
Exclusion criteria
1. Absent or limited legal capacity
2. Pregnant or lactating women
3. Serious primary diseases in major organs
4. Mental or physical disability preventing the
completion of 6MWD
5. Suspected or confirmed history of alcohol or
substance abuse
6. Known allergy to the components of TMP
7. AST and ALT values more than three times the
upper limit of normal, or creatinine clearance
rate < 50 ml/min
8. Low systemic blood pressure (< 90/50 mmHg) or
uncontrolled hypertension (blood pressure > 170/
110 mmHg)
9. Prior use of the study drug and discontinuation or
change in targeted drugs (e.g., endothelin receptor
antagonists, phosphodiesterase type 5 inhibitors, and
guanylate cyclase) in the 3 months prior to screening
10. Presence of an active infectious disease such as
hepatitis A, hepatitis B, AIDS, tuberculosis, or
connective tissue diseases
11. Presence of serious infection, especially pulmonary
infections
12. Shock or other hemodynamically unstable conditions
13. Cirrhosis or portal hypertension caused by cirrhosis
14. Severe bleeding or bleeding tendency such as active
peptic ulcer, intracranial hemorrhage, trauma, or
other bleeding events
15. Acute or chronic organic diseases (except for
dyspnea) or other conditions (such as limb diseases)
that may result in the subject being unable to
complete the study (especially the 6MWD)
16. Use or accidental use of foods or drugs that may
impact test results during the treatment period
(e.g., amirace, fenfluramine, dexfenfluramine, L-
tryptophan, methamphetamine, and
phenylflurazone)
17. Any other circumstances under which the
investigator considers the patient to be unsuitable
for participation in the study
Withdrawal criteria
1. Subjects having poor compliance with the dosing
regimen
2. Use or accidental use of foods or drugs that may
impact test results during the treatment period
(e.g., amirace, fenfluramine, dexfenfluramine, L-
tryptophan, methamphetamine, and
phenylflurazone)
3. Subjects with incomplete key data that may affect
the statistical analysis
Endpoint standards
1. Subjects experiencing serious adverse reactions
leading to suspension or termination of treatment
during the study
2. Subjects whose condition deteriorates during the
study
3. Subjects who withdraw consent or are unable to
complete the study because of other circumstances
4. Patients treated with targeted drugs for type 1 or 4
PH prior to testing who stopped treatment with the
targeted drug for any reason during the study and
did not reinitiate treatment
5. Death (from PH or another cause)
Interventions Subjects satisfying all criteria will be
assigned (2:1) randomly into two groups as follows:
1. TMP treatment group: TMP 100 mg three times
daily in addition to routine therapy
2. Control group: routine therapy only
The routine therapy follows the 2015 ESC Guideline.
The current treatment strategy for PAH patients can be
divided into three main steps:
(1) The initial approach includes general measures
(physical activity and supervised rehabilitation,
pregnancy, birth control and post-menopausal hor-
monal therapy, elective surgery, infection preven-
tion, psychosocial support, adherence to treatments,
genetic counseling and travel), supportive therapy
(oral anticoagulants, diuretics, O2, digoxin), referral
to expert centers and acute vasoreactivity testing
for the indication of chronic Calcium Channel
Blocker (CCB) therapy.
(2) The second step includes initial therapy with high-
dose CCB in vasoreactive patients or drugs approved
for PAH in non-vasoreactive patients according to
the prognostic risk of the patient and the grade of
recommendation and level of evidence for each indi-
vidual compound or combination of compounds.
(3) The third part is related to the response to the
initial treatment strategy; in case of an inadequate
response, the role of combinations of approved
drugs and lung transplantation are proposed.
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It is important to monitor renal function and blood
biochemistry in patients with diuretic use to avoid hypo-
kalaemia and the effects of decreased intravascular vol-
ume leading to pre-renal failure.
Optimal medical treatment for Chronic Thrombo-
embolic Pulmonary Hypertension (CTEPH) consists of
anticoagulants and diuretics, and O2 in cases of heart
failure or hypoxaemia.
TMP was produced by Livzon Pharmaceutical Group
Inc. (Zhuhai, Guangdong Province, China), following the
instructions of the People’s Republic of China
Pharmacopoeia [22]. Routine therapy will not differ be-
tween the two groups and will include phosphodiesterase
type 5 inhibitors (sildenafil and tadalafil). Where subjects
have previously received targeted drugs for the treatment
of PH, the regimen will remain unchanged.
Outcome measures
Efficacy indicators The main efficacy indicators are
6MWD and heart rate recovery at 1 min after the
6MWD (Table 2).
Secondary efficacy measurements include the following
12 indicators (Table 2): PH WHO classification, Borg
Dyspnea Score, Minnesota Living with Heart Failure
Questionnaire, N-terminal pro-brain natriuretic peptide,
cardiac troponin I, right ventricular systolic pressure eval-
uated by echocardiogram, uric acid, volume of pericardial
effusion, pulmonary artery diameter assessed by CT,
diameter of the same layer of aorta assessed by CT, arter-
ial oxygen saturation, and time of clinical deterioration.
Safety evaluation
Symptoms and signs including respiration rate, heart
rate, and blood pressure will be recorded at each visit.
Laboratory tests will be performed within 3 days prior to
enrollment and will include routine blood tests and urin-
alysis, liver function, renal function, coagulation func-
tion, NT-proBNP, and electrocardiography. Adverse
events will be assessed and recorded in the case report
form.
Evaluation of adverse events
Adverse events, including symptoms, signs, and physical
or laboratory examination abnormalities, will be care-
fully evaluated. All adverse events must be judged for
their character, severity, and potential relationship to the
study treatment. The correlation between adverse events
and study treatment is divided into five levels: defin-
itely related, probabley related, possiblely related, possi-
blely unrelated, definitely unrelated.
Treatment allocation As the study is single-blind, only
the participant will be unaware of which treatment they
receive; those responsible for their care and evaluation
(treating team and research team) will know the alloca-
tion or coding of the treatment allocation. This blinding
of the participant will be achieved by identical packaging
and labeling of both the TMP tablet and matched pla-
cebo. Each container of TMP/placebo will be identified
by a unique kit code. Randomized lists containing kit al-
location will be computer-generated by the safety statis-
tician and sent to the research investigator who will
produce the kits and allocation sequence. The safety
statistician will manage the kit codes in the kit logistics
application, which is linked to the 24-h randomization
system, and will maintain the back-up kit-code lists for
each site.
Data management and analysis
General considerations
Per protocol set will pick up from the full analysis set
for analysis. Statistical analysis of the efficacy of the
study will be performed using statistical data sets that
meet the protocol. The data will be analyzed by two-
sided t test, with categorical variables analyzed by χ2 test
and rank variables by paired Wilcoxon rank sum test.
The test level α is 0.05, and P values ≤ 0.05 will be con-
sidered statistically significant.
The methods that will be used to handle missing data
are described for each analysis. As this is a single-blind
study, the study statistician will be blinded to treatment
group allocation throughout the study until the database
has been locked and downloaded for final analysis. Only
the safety statistician, supervising study statistician,
back-up safety statistician, and authorized individuals






Pulmonary hypertension WHO classification
Borg Dyspnea Score






Volume of pericardial effusion
Pulmonary artery diameter
Diameter of the same layer of aorta
Arterial oxygen saturation
Time of clinical deterioration
Clinical deterioration is defined as the need to increase medication or change
the therapeutic regimen for the treatment of PH, particularly inhaled,
intravenous, or subcutaneous application of prostacyclin and its analogues;
aggravated symptoms of right heart failure that do not respond to diuretics;
atrial septostomy or death; lung transplantation; or hospitalization caused by
exacerbation of PH
Other clinical symptoms and signs, biochemical indicators, and imaging
indicators are recorded (Table 2) for comprehensive prognostic evaluation and
risk assessment
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will have access to the treatment group allocations prior
to the final analysis.
Frequency of analyses
Outcome data will be analyzed once only, at the final
analysis, although statistical monitoring of safety data
will be conducted throughout the study and reported at
agreed intervals. Final analysis will take place 16 weeks
after the last patient is randomized.
Endpoint analysis
All analyses will be conducted using data from the
intention-to-treat population, defined as all patients who
undergo randomization regardless of non-compliance
with the intervention. The primary endpoint will be ana-
lyzed in the per-protocol population to determine
whether the results are sensitive to the exclusion of pa-
tients who violated the protocol (e.g., those patients who
underwent randomization but were subsequently found
to be ineligible). Primary and secondary analyses will be
performed by an investigator who is unblinded to treat-
ment allocation. Outcome measures will be analyzed by
χ2 test and rank variables by paired Wilcoxon rank sum
test appropriate for the data type. Such analyses will be
adjusted for randomization minimization factors such as
baseline values where applicable (such as age and sex).
Baseline characteristics will be summarized for each ran-
domized group.
Safety analyses
All patients who receive at least one dose of trial treat-
ment will be included in the safety analysis set. The
number of patients reporting a serious adverse event (up
to 28 days after the last dose of treatment) and the de-
tails of all serious adverse events will be reported for
each treatment group. The number of patients with-
drawing from treatment will be summarized by treat-
ment arm, along with the reasons for withdrawal. All
safety analyses performed prior to final analysis will be
undertaken by the safety statistician.
Subgroup analyses
No subgroup analyses are planned.
Adverse events
An adverse event is defined as any untoward medical oc-
currence (including deterioration of a pre-existing med-
ical condition) in a patient who has been administered a
medicinal product; the event does not necessarily have a
causal relationship with this product. The occurrence of
adverse events will be recorded at visits 1–4. At each
visit, the research nurse will complete the adverse event
checklist to determine whether the patient has experi-
enced any of the expected adverse events. Only the
occurrence and corresponding severity of adverse events
will be recorded.
Ethics
The present study is being conducted in accordance with
the Declaration of Helsinki and relevant clinical study re-
search regulations in China. The protocol was approved
by the Ethics Committee of the First Affiliated Hospital of
Guangzhou Medical University. Prior to participation, all
subjects must provide written informed consent. Our
protocol followed the SPIRIT 2013 Checklist, which
provided specific details in the Additional file 1.
Discussion
To date, many targeted drugs have emerged for the
treatment of PH; however, these drugs are limited by
unsatisfactory long-term efficacy and their expensive
price. Ligustrazine is an alkaloid extracted from the trad-
itional Chinese medicine herb Ligusticum wallichiii
Franch (i.e., Ligusticum chuanxiong Hort). TMP has a
variety of cardio-cerebral vascular pharmacological ef-
fects such as protection of vascular endothelium and an-
tiplatelet, anti-ischemia reperfusion injury, antioxidative
stress, etc. actions [22]. Moreover, TMP has been widely
used in Chinese clinics for the treatment of occlusive
cardiovascular and cerebrovascular diseases such as cor-
onary heart disease, cerebral thrombosis, and vasculitis
[22]. TMP has also been reported for the treatment of
various diseases such as cor pulmonale, heart disease,
kidney disease, portal hypertension, type 2 diabetes, tu-
mors, and restenosis after coronary stenting in recent
years [23–29]. At present, TMP phosphate tablets are
one of the most commonly used drugs in clinical prac-
tice in China. Some basic research has shown that treat-
ment with TMP decreases the permeability of the
hypoxia-induced rat pulmonary microvascular endothe-
lial cell monolayer such that it can be used to treat pul-
monary hypertension [30, 31]. However, there is little
evidence to date on the efficacy and safety of TMP ther-
apy for PH. We conducted a literature search on the side
effects of TMP; all the current reported side effects are
from injections, including phlebitis, chills, fever, rash,
itching, chest tightness, palpitations, dizziness, dyspnea,
sore throat, and so on [32, 33]. We found that no report
has yet evaluated the adverse events associated with oral
TMP treatment, and there is also no information on the
National Center for ADR, China website (http://www.
cdr-adr.org.cn/). The clinical observation of our own
hospital has confirmed that oral intake of TMP is safe,
without obvious adverse reactions. Thus, the present
clinical study is expected to provide evidence for the
safety and efficacy of TMP, a new affordable potential
treatment for PH.
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There are some limitations in this clinical study. Due
to TMP’s odor, we set the study as a single-blinded clin-
ical study. Also, the scale of this clinical study is rela-
tively small. We plan to conduct a subsequent large-
scale clinical study comprehensively evaluating the effi-
cacy and safety of TMP in the treatment of PH based on
the findings of the present study.
Trial status
Recruitment started in September 2018 and is planned
to end in October 2018, with 120 patients randomized.
Treatment with TMP finished in October 2019. We dis-
posal the data at present. The current protocol version is
2.0, dated 28 September 2018.
Additional file
Additional file 1. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*.
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